GeneDx Faces Shareholder Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 31 minutes ago
0mins
Source: Globenewswire
- Lawsuit Background: GeneDx Holdings Corp. is facing a shareholder class action lawsuit alleging that it made false statements and failed to disclose material adverse facts regarding its acquisition of Fabric Genomics, which negatively impacted investors' interests.
- Investor Impact: Shareholders who purchased GeneDx shares between April 16, 2025, and May 4, 2026, and experienced losses are encouraged to contact legal counsel to discuss their rights, highlighting concerns over corporate transparency and governance.
- Legal Representation: Holzer & Holzer, LLC, a highly rated securities litigation law firm, is dedicated to vigorously representing shareholders and investors, indicating that this case may attract significant legal scrutiny and subsequent actions.
- Lawsuit Deadline: Investors must apply to be appointed lead plaintiff by August 3, 2026, emphasizing the urgency of the legal process and the potential role of investors in this case.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WGS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WGS
Wall Street analysts forecast WGS stock price to rise
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 56.270
Low
155.00
Averages
171.43
High
200.00
Current: 56.270
Low
155.00
Averages
171.43
High
200.00
About WGS
GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GeneDx Shares Plunge 49% Following Earnings Miss and Guidance Cut
- Earnings Disaster: GeneDx reported a tenfold increase in net loss for Q1 2026, causing a 49% drop in share price and erasing over $900 million in market capitalization, severely undermining investor confidence.
- Guidance Downgrade: The company slashed its 2026 revenue guidance by 12%, stating that growth in genome and exome revenue would be at least 20%, significantly lower than previous expectations, indicating a sharp slowdown in business growth.
- Legal Investigation Launched: Following the stock plunge, Hagens Berman law firm has initiated an investigation into whether GeneDx intentionally or recklessly misled investors, potentially facing legal repercussions that could further exacerbate market anxiety.
- Revenue Source Shift: GeneDx's average reimbursement rate (ARR) fell in 2026, primarily due to a significant change in product mix, with genome ARR being only half that of exome, impacting the company's revenue structure and future growth potential.
See More
GeneDx Faces Shareholder Class Action Lawsuit
- Lawsuit Background: GeneDx Holdings Corp. is facing a shareholder class action lawsuit alleging that it made false statements and failed to disclose material adverse facts regarding its acquisition of Fabric Genomics, which negatively impacted investors' interests.
- Investor Impact: Shareholders who purchased GeneDx shares between April 16, 2025, and May 4, 2026, and experienced losses are encouraged to contact legal counsel to discuss their rights, highlighting concerns over corporate transparency and governance.
- Legal Representation: Holzer & Holzer, LLC, a highly rated securities litigation law firm, is dedicated to vigorously representing shareholders and investors, indicating that this case may attract significant legal scrutiny and subsequent actions.
- Lawsuit Deadline: Investors must apply to be appointed lead plaintiff by August 3, 2026, emphasizing the urgency of the legal process and the potential role of investors in this case.
See More
GeneDx Faces Securities Class Action After 49% Stock Plunge
- Stock Plunge: GeneDx's stock price plummeted by $33.42 (-49%) on May 5, 2026, following a disastrous Q1 2026 earnings report, severely undermining investor confidence and potentially triggering widespread sell-offs.
- Lawsuit Background: Hagens Berman is investigating whether GeneDx violated federal securities laws, with the lawsuit aiming to represent investors who purchased shares between April 16, 2025, and May 4, 2026, seeking compensation for their losses.
- Deteriorating Financial Performance: GeneDx reported a tenfold increase in net loss for Q1 2026 compared to the previous year, with the Fabric Genomics business missing revenue targets and leading to a $31.2 million impairment charge, significantly impacting the company's financial health.
- Revenue Guidance Cut: The company slashed its 2026 revenue guidance by 12%, stating that genome and exome revenue growth would be at least 20%, a stark decline from previous expectations, reflecting significant changes in product mix and negative implications for future growth.
See More
GeneDx Shareholder Class Action Notice Issued
- Lawsuit Timeline: Shareholders of GeneDx Holdings Corp. who purchased common stock between April 16, 2025, and May 4, 2026, must apply by August 3, 2026, to serve as lead plaintiff in the class action lawsuit, highlighting investor concerns over corporate governance and transparency.
- Allegations Overview: The class action lawsuit accuses GeneDx and its executives of violating the Securities Exchange Act of 1934, claiming they failed to disclose significant financial issues regarding the acquisition of Fabric Genomics, which could negatively impact the company's overall operations.
- Financial Loss Disclosure: The Q1 2026 financial report revealed a drop in adjusted gross margin from 74% to 69%, a reduction in projected earnings from $540-$555 million to $475-$490 million, and a $31.3 million impairment loss attributed to Fabric Genomics, reflecting the risks and potential financial crisis associated with the acquisition.
- Stock Price Plunge Impact: Following the earnings report, GeneDx's stock price plummeted over 49%, which not only undermines investor confidence but may also complicate the company's future financing and competitive positioning, underscoring the consequences of insufficient transparency.
See More
GeneDx Shares Plunge 49% Following Earnings Miss and Investigation Launch
- Earnings Miss: GeneDx reported a tenfold increase in net loss for Q1 2026, leading to a 49% drop in share price on May 5, 2025, which wiped out over $900 million in market capitalization, indicating a severe deterioration in the company's financial health.
- Guidance Cut: The company slashed its 2026 revenue guidance by 12% and stated that revenue growth for genome and exome tests would drop to at least 20%, contrasting sharply with previous expectations of 33%-35%, reflecting a pessimistic market outlook on future growth.
- Investigation Launched: Following the stock plunge, Hagens Berman law firm has initiated an investigation into whether GeneDx intentionally or recklessly misled investors, potentially facing legal repercussions, which further exacerbates investor anxiety.
- Severe Market Reaction: The drastic decline in GeneDx's stock price not only undermines investor confidence but may also pose greater challenges for the company in future financing and business expansion, impacting its competitive position in the market.
See More
Class Action Lawsuit Filed Against GeneDx Holdings Corp.
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against GeneDx Holdings Corp. aimed at recovering damages for investors who purchased securities between April 16, 2025, and May 4, 2026, highlighting significant transparency issues regarding the company's financial disclosures.
- Allegations Details: The complaint alleges that the company failed to disclose critical information about the importance of Fabric Genomics and its impact on profit margins, which could severely undermine investor confidence and lead to a decline in stock prices.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by August 3, 2026, to participate in potential recovery, demonstrating the legal system's role in protecting investor rights and interests.
- Legal Fee Arrangement: The law firm operates on a contingency fee basis, meaning they will only charge fees if they successfully recover damages, thereby reducing financial risk for investors and encouraging their participation in the lawsuit.
See More
GeneDx Shares Plunge 49% Following Earnings Miss and Guidance Cut
- Earnings Disaster: GeneDx reported a tenfold increase in net loss for Q1 2026, causing a 49% drop in share price and erasing over $900 million in market capitalization, severely undermining investor confidence.
- Guidance Downgrade: The company slashed its 2026 revenue guidance by 12%, stating that growth in genome and exome revenue would be at least 20%, significantly lower than previous expectations, indicating a sharp slowdown in business growth.
- Legal Investigation Launched: Following the stock plunge, Hagens Berman law firm has initiated an investigation into whether GeneDx intentionally or recklessly misled investors, potentially facing legal repercussions that could further exacerbate market anxiety.
- Revenue Source Shift: GeneDx's average reimbursement rate (ARR) fell in 2026, primarily due to a significant change in product mix, with genome ARR being only half that of exome, impacting the company's revenue structure and future growth potential.
See More
GeneDx Faces Shareholder Class Action Lawsuit
- Lawsuit Background: GeneDx Holdings Corp. is facing a shareholder class action lawsuit alleging that it made false statements and failed to disclose material adverse facts regarding its acquisition of Fabric Genomics, which negatively impacted investors' interests.
- Investor Impact: Shareholders who purchased GeneDx shares between April 16, 2025, and May 4, 2026, and experienced losses are encouraged to contact legal counsel to discuss their rights, highlighting concerns over corporate transparency and governance.
- Legal Representation: Holzer & Holzer, LLC, a highly rated securities litigation law firm, is dedicated to vigorously representing shareholders and investors, indicating that this case may attract significant legal scrutiny and subsequent actions.
- Lawsuit Deadline: Investors must apply to be appointed lead plaintiff by August 3, 2026, emphasizing the urgency of the legal process and the potential role of investors in this case.
See More
GeneDx Faces Securities Class Action After 49% Stock Plunge
- Stock Plunge: GeneDx's stock price plummeted by $33.42 (-49%) on May 5, 2026, following a disastrous Q1 2026 earnings report, severely undermining investor confidence and potentially triggering widespread sell-offs.
- Lawsuit Background: Hagens Berman is investigating whether GeneDx violated federal securities laws, with the lawsuit aiming to represent investors who purchased shares between April 16, 2025, and May 4, 2026, seeking compensation for their losses.
- Deteriorating Financial Performance: GeneDx reported a tenfold increase in net loss for Q1 2026 compared to the previous year, with the Fabric Genomics business missing revenue targets and leading to a $31.2 million impairment charge, significantly impacting the company's financial health.
- Revenue Guidance Cut: The company slashed its 2026 revenue guidance by 12%, stating that genome and exome revenue growth would be at least 20%, a stark decline from previous expectations, reflecting significant changes in product mix and negative implications for future growth.
See More
GeneDx Shareholder Class Action Notice Issued
- Lawsuit Timeline: Shareholders of GeneDx Holdings Corp. who purchased common stock between April 16, 2025, and May 4, 2026, must apply by August 3, 2026, to serve as lead plaintiff in the class action lawsuit, highlighting investor concerns over corporate governance and transparency.
- Allegations Overview: The class action lawsuit accuses GeneDx and its executives of violating the Securities Exchange Act of 1934, claiming they failed to disclose significant financial issues regarding the acquisition of Fabric Genomics, which could negatively impact the company's overall operations.
- Financial Loss Disclosure: The Q1 2026 financial report revealed a drop in adjusted gross margin from 74% to 69%, a reduction in projected earnings from $540-$555 million to $475-$490 million, and a $31.3 million impairment loss attributed to Fabric Genomics, reflecting the risks and potential financial crisis associated with the acquisition.
- Stock Price Plunge Impact: Following the earnings report, GeneDx's stock price plummeted over 49%, which not only undermines investor confidence but may also complicate the company's future financing and competitive positioning, underscoring the consequences of insufficient transparency.
See More
GeneDx Shares Plunge 49% Following Earnings Miss and Investigation Launch
- Earnings Miss: GeneDx reported a tenfold increase in net loss for Q1 2026, leading to a 49% drop in share price on May 5, 2025, which wiped out over $900 million in market capitalization, indicating a severe deterioration in the company's financial health.
- Guidance Cut: The company slashed its 2026 revenue guidance by 12% and stated that revenue growth for genome and exome tests would drop to at least 20%, contrasting sharply with previous expectations of 33%-35%, reflecting a pessimistic market outlook on future growth.
- Investigation Launched: Following the stock plunge, Hagens Berman law firm has initiated an investigation into whether GeneDx intentionally or recklessly misled investors, potentially facing legal repercussions, which further exacerbates investor anxiety.
- Severe Market Reaction: The drastic decline in GeneDx's stock price not only undermines investor confidence but may also pose greater challenges for the company in future financing and business expansion, impacting its competitive position in the market.
See More
Class Action Lawsuit Filed Against GeneDx Holdings Corp.
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against GeneDx Holdings Corp. aimed at recovering damages for investors who purchased securities between April 16, 2025, and May 4, 2026, highlighting significant transparency issues regarding the company's financial disclosures.
- Allegations Details: The complaint alleges that the company failed to disclose critical information about the importance of Fabric Genomics and its impact on profit margins, which could severely undermine investor confidence and lead to a decline in stock prices.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by August 3, 2026, to participate in potential recovery, demonstrating the legal system's role in protecting investor rights and interests.
- Legal Fee Arrangement: The law firm operates on a contingency fee basis, meaning they will only charge fees if they successfully recover damages, thereby reducing financial risk for investors and encouraging their participation in the lawsuit.
See More
